Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neuroendocrine Tumors
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Receptors, Somatostatin
/ metabolism
Rectal Neoplasms
/ diagnostic imaging
Retrospective Studies
Treatment Outcome
Lutetium
Neuroendocrine
PRRT
Radionuclide therapy
Rectal
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
31
07
2018
accepted:
11
10
2018
pubmed:
22
10
2018
medline:
14
6
2019
entrez:
22
10
2018
Statut:
ppublish
Résumé
Rectal neuroendocrine neoplasia (NEN) is more common than other NEN origins, but is less commonly metastatic. However, when present, distant disease carries a particularly poor prognosis. Evidence guiding optimal treatment of such patients is lacking. We assessed PRRT outcomes in patients with somatostatin receptor (SSTR) positive metastatic rectal NEN from two referral centres. Patients treated with PRRT were retrospectively reviewed. Morphologic (RECIST 1.1), SSTR imaging responses and toxicity were assessed 3 months post-PRRT. Kaplan-Meier estimate was used to determine progression-free survival (PFS) and overall survival (OS) from start of PRRT. Twenty-seven consecutive patients (M = 20, age 31-81 years) were reviewed. The majority (70%) had ENETs grade 2 disease (19 patients), three had Grade 3, one Grade 1, and four not documented. Overall, 63% (10/16 patients with available FDG PET/CT) had FDG avid disease. Twenty-six patients were treated for disease progression. Most had Our results indicate high efficacy and morphologic responses with minimal toxicity and very encouraging survival from PRRT in patients with metastatic rectal NEN despite the adverse prognostic features of this cohort. Further prospective PRRT trials are warranted in this subgroup.
Identifiants
pubmed: 30343432
doi: 10.1007/s00259-018-4196-8
pii: 10.1007/s00259-018-4196-8
doi:
Substances chimiques
Receptors, Somatostatin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
718-727Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Oncologist. 2013;18(1):46-53
pubmed: 23263288
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1869-75
pubmed: 20445977
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Neuroendocrinology. 2016;103(2):139-43
pubmed: 26730835
Neuroendocrinology. 2013;98(3):180-7
pubmed: 24080744
Neuroendocrinology. 2016;103(2):186-94
pubmed: 26731334
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):476-489
pubmed: 27678267
Cancer Biother Radiopharm. 2009 Oct;24(5):527-33
pubmed: 19877882
Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S219-23
pubmed: 10604135
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11
pubmed: 21052661
Cancer Treat Rev. 2016 Nov;50:61-67
pubmed: 27636009
Clin Nucl Med. 2015 Oct;40(10):799-801
pubmed: 26204211
ANZ J Surg. 2017 Jan;87(1-2):92-93
pubmed: 25307828
Endocrine. 2017 Nov;58(2):368-379
pubmed: 28303513
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1831-44
pubmed: 24844348
Neuroendocrinology. 2012;95(2):88-97
pubmed: 22261972
N Engl J Med. 2014 Oct 16;371(16):1556-7
pubmed: 25317881
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
Ann Oncol. 2010 May;21 Suppl 5:v223-7
pubmed: 20555086
Endocr Relat Cancer. 2010 Oct 05;17(4):909-18
pubmed: 20702725